US1017286A
(en)
|
1909-03-01 |
1912-02-13 |
Du Pont Powder Co |
Apparatus for treating explosive powder.
|
US1000578A
(en)
|
1910-01-12 |
1911-08-15 |
Robert T Burdette |
Power-driven post-hole excavator.
|
US1001160A
(en)
|
1910-04-05 |
1911-08-22 |
Paul A Otto |
Aerodrome.
|
US1004709A
(en)
|
1910-05-20 |
1911-10-03 |
Albert E Yerkes |
Spraying device.
|
US1004599A
(en)
|
1910-06-14 |
1911-10-03 |
C F Splitdorf |
Armature for electric generators.
|
US1013712A
(en)
|
1911-06-03 |
1912-01-02 |
Alfred D Williams |
Tie and rail-fastener.
|
NZ234143A
(en)
|
1989-06-28 |
1991-10-25 |
Mcneil Ppc Inc |
Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
|
RU2139281C1
(ru)
|
1993-11-30 |
1999-10-10 |
Джи Ди Сирл энд Компани |
Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
|
US5844092A
(en)
|
1994-03-18 |
1998-12-01 |
Genentech, Inc. |
Human TRK receptors and neurotrophic factor inhibitors
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5430021A
(en)
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
US6458811B1
(en)
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
CA2206201A1
(en)
|
1996-05-29 |
1997-11-29 |
Yoshiaki Isobe |
Pyrazole derivatives and their pharmaceutical use
|
JP3898296B2
(ja)
|
1996-08-28 |
2007-03-28 |
ポーラ化成工業株式会社 |
ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
|
ATE283270T1
(de)
|
1997-04-25 |
2004-12-15 |
Takeda Chemical Industries Ltd |
Condensierte pyridazine derivate,deren herstellung und verwendung
|
NZ511995A
(en)
|
1999-01-21 |
2003-11-28 |
Bristol Myers Squibb Co |
A ras-farnesyltransferase inhibitor complex that is stable and water soluble and useful as an anti-tumour agent
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6534085B1
(en)
|
1999-09-23 |
2003-03-18 |
Bioresponse L.L.C. |
Phytochemicals for promoting weight loss
|
EP1292680B1
(en)
|
2000-06-22 |
2009-10-21 |
Genentech, Inc. |
Agonist anti-trk-c monoclonal antibodies
|
GB0028575D0
(en)
|
2000-11-23 |
2001-01-10 |
Elan Corp Plc |
Oral pharmaceutical compositions containing cyclodextrins
|
IL156487A0
(en)
|
2000-12-22 |
2004-01-04 |
Astrazeneca Ab |
Carbazole derivatives and their use as neuropeptide y5 receptor ligands
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
BR0207930A
(pt)
*
|
2001-03-05 |
2004-03-02 |
Ortho Mcneil Pharm Inc |
Composições farmacêuticas lìquidas com sabor mascarado
|
EP2340849A1
(en)
|
2001-05-30 |
2011-07-06 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
US7101572B2
(en)
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
US20030199525A1
(en)
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
CA2483306A1
(en)
|
2002-04-23 |
2003-11-06 |
Shionogi & Co., Ltd. |
Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
|
US7449488B2
(en)
|
2002-06-04 |
2008-11-11 |
Schering Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
ITMI20021620A1
(it)
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
JP4024624B2
(ja)
|
2002-08-26 |
2007-12-19 |
富士通株式会社 |
半導体装置の製造方法及び製造装置
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
KR101088922B1
(ko)
|
2002-09-04 |
2011-12-01 |
파마코페이아, 엘엘씨. |
사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
|
US7196078B2
(en)
|
2002-09-04 |
2007-03-27 |
Schering Corpoartion |
Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US7119200B2
(en)
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
WO2004052286A2
(en)
|
2002-12-11 |
2004-06-24 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
JP4634367B2
(ja)
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004082458A2
(en)
|
2003-02-21 |
2004-09-30 |
The Johns Hopkins University |
Tyrosine kinome
|
JP2004277337A
(ja)
|
2003-03-14 |
2004-10-07 |
Sumitomo Pharmaceut Co Ltd |
ピラゾロ[1,5−a]ピリミジン誘導体
|
EP1608652A1
(en)
|
2003-03-31 |
2005-12-28 |
Vernalis (Cambridge) Limited |
Pyrazolopyrimidine compounds and their use in medicine
|
US20060094699A1
(en)
|
2003-04-11 |
2006-05-04 |
Kampen Gita Camilla T |
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
|
JP2006522744A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
|
EP1615697A2
(en)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
|
KR20060011977A
(ko)
|
2003-04-28 |
2006-02-06 |
가르파마 컴퍼니 리미티드 |
갈렉틴 9 유도 인자
|
JO2785B1
(en)
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
JP2005008581A
(ja)
|
2003-06-20 |
2005-01-13 |
Kissei Pharmaceut Co Ltd |
新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
|
EA009517B1
(ru)
|
2003-06-27 |
2008-02-28 |
Байер Кропсайенс Аг |
Пиразолопиримидины
|
EP2364728A1
(en)
|
2003-07-15 |
2011-09-14 |
Amgen, Inc |
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
WO2005044835A1
(en)
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
|
MY141220A
(en)
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
RU2006122853A
(ru)
|
2003-11-28 |
2008-01-10 |
Новартис АГ (CH) |
Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
|
EP1697384B1
(en)
|
2003-12-18 |
2008-04-02 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
|
DK1696920T3
(en)
|
2003-12-19 |
2015-01-19 |
Plexxikon Inc |
RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
|
WO2005068424A1
(en)
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
WO2005099363A2
(en)
|
2004-03-26 |
2005-10-27 |
Whitehead Institute For Biomedical Research |
Methods of diagnosing, preventing and treating cancer metastasis
|
CN1938311A
(zh)
|
2004-03-30 |
2007-03-28 |
因特蒙公司 |
作为病毒复制抑制剂的大环化合物
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
ZA200704476B
(en)
|
2004-11-04 |
2008-09-25 |
Vertex Pharma |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
|
JO3088B1
(ar)
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
PT1853602E
(pt)
|
2005-02-16 |
2010-08-25 |
Astrazeneca Ab |
Compostos químicos
|
CN101119996A
(zh)
|
2005-02-16 |
2008-02-06 |
阿斯利康(瑞典)有限公司 |
化学化合物
|
PL1869049T3
(pl)
|
2005-03-21 |
2009-07-31 |
Lilly Co Eli |
Związki imidazopirydazyny
|
CN101208093A
(zh)
|
2005-04-27 |
2008-06-25 |
阿斯利康(瑞典)有限公司 |
吡唑-嘧啶衍生物在治疗疼痛中的用途
|
MX2007014328A
(es)
|
2005-05-16 |
2008-02-12 |
Astrazeneca Ab |
Compuestos quimicos.
|
CN100406650C
(zh)
|
2005-06-05 |
2008-07-30 |
徐斌 |
一种抗特大变位的模块式梳型桥梁伸缩缝装置
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
DK1893612T3
(da)
|
2005-06-22 |
2011-11-21 |
Plexxikon Inc |
Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
|
US20070025540A1
(en)
|
2005-07-07 |
2007-02-01 |
Roger Travis |
Call center routing based on talkativeness
|
EP2305696A3
(en)
|
2005-07-25 |
2011-10-12 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
US20070184117A1
(en)
|
2005-08-03 |
2007-08-09 |
Stephen Gregory |
Tocopheryl polyethylene glycol succinate powder and process for preparing same
|
US20070191306A1
(en)
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
CA2619365A1
(en)
|
2005-08-22 |
2007-03-01 |
Amgen Inc. |
Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
CA2620032C
(en)
|
2005-08-25 |
2014-02-04 |
Creabilis Therapeutics S.P.A. |
Polymer conjugates of k-252a and derivatives thereof
|
DE102005042742A1
(de)
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
US20070078136A1
(en)
|
2005-09-22 |
2007-04-05 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
CN101316847A
(zh)
|
2005-10-06 |
2008-12-03 |
先灵公司 |
用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
|
JP5152922B2
(ja)
|
2005-10-06 |
2013-02-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
|
KR20080056295A
(ko)
|
2005-10-11 |
2008-06-20 |
인터뮨, 인크. |
C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
|
CA2624772C
(en)
|
2005-10-11 |
2011-11-29 |
Centre National De La Recherche Scientifique (Cnrs) |
Compounds and kits for the detection and the quantification of cell apoptosis
|
US8372851B2
(en)
|
2005-10-21 |
2013-02-12 |
Exelixis, Inc. |
Pyrazolo pyrimidines as casein kinase II (CK2) modulators
|
WO2007057399A2
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer with indole derivatives
|
GB0524436D0
(en)
|
2005-11-30 |
2006-01-11 |
Novartis Ag |
Organic compounds
|
US20070166336A1
(en)
*
|
2005-12-13 |
2007-07-19 |
David Delmarre |
Stable and palatable oral liquid sumatriptan compositions
|
JP5474354B2
(ja)
|
2005-12-30 |
2014-04-16 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
WO2007084815A2
(en)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica, N.V. |
Substituted thienopyrimidine kinase inhibitors
|
WO2007087245A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Ret tyrosine kinase inhibition
|
WO2007102679A1
(en)
|
2006-03-06 |
2007-09-13 |
Je Il Pharmaceutical Co., Ltd. |
Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
|
US7723330B2
(en)
|
2006-03-07 |
2010-05-25 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
TWI394749B
(zh)
|
2006-03-27 |
2013-05-01 |
內維亞諾醫學公司 |
具有激酶抑制劑活性之雜戊環
|
GB0606805D0
(en)
|
2006-04-04 |
2006-05-17 |
Novartis Ag |
Organic compounds
|
UA95799C2
(en)
|
2006-04-26 |
2011-09-12 |
Ф. Хоффманн-Ля Рош Аг |
Pharmaceutical compounds
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
US7389632B2
(en)
|
2006-06-10 |
2008-06-24 |
Uhlmann Pac-Systeme Gmbh & Co. Kg |
Apparatus for distributing small objects in a fill station
|
EP1873157A1
(en)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
TWI419889B
(zh)
|
2006-07-05 |
2013-12-21 |
Mitsubishi Tanabe Pharma Corp |
吡唑并〔1,5-a〕嘧啶化合物
|
EP2058309A4
(en)
|
2006-08-04 |
2010-12-22 |
Takeda Pharmaceutical |
CONDENSED HETEROCYCLIC COMPOUND
|
CL2007002261A1
(es)
|
2006-08-04 |
2008-05-02 |
Takeda Pharmaceutical |
Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
|
US7531539B2
(en)
|
2006-08-09 |
2009-05-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
EP2063962A2
(en)
|
2006-09-07 |
2009-06-03 |
Biogen Idec MA Inc. |
Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
US20110195072A1
(en)
|
2006-09-12 |
2011-08-11 |
Anne Boulay |
Non-neuroendocrine cancer therapy
|
AU2007302263A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as P13K lipid kinase inhibitors
|
WO2008052734A1
(en)
|
2006-10-30 |
2008-05-08 |
Novartis Ag |
Heterocyclic compounds as antiinflammatory agents
|
BRPI0718029A2
(pt)
|
2006-11-06 |
2013-11-26 |
Supergen Inc |
Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
|
PE20121126A1
(es)
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
AU2007336811A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2008079909A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
US7820684B2
(en)
|
2007-03-01 |
2010-10-26 |
Supergen, Inc. |
Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
|
US20080234267A1
(en)
|
2007-03-20 |
2008-09-25 |
Karen Elizabeth Lackey |
Compounds and Methods of Treatment
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
EP2137187A1
(en)
|
2007-03-28 |
2009-12-30 |
Inovacia AB |
Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
|
RU2467008C2
(ru)
|
2007-04-03 |
2012-11-20 |
Эррэй Биофарма Инк. |
СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ
|
BRPI0811516A2
(pt)
|
2007-05-04 |
2014-11-18 |
Irm Llc |
Compostos e composições como inibidores de c-kit e pdgfr cinase
|
ES2435454T3
(es)
|
2007-06-21 |
2013-12-19 |
Janssen Pharmaceutica, N.V. |
Indolin-2-onas y aza-indolin-2-onas
|
AU2008273889B2
(en)
|
2007-07-09 |
2012-03-08 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
JP5241834B2
(ja)
|
2007-07-19 |
2013-07-17 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼ阻害剤としての複素環アミド化合物
|
CA2693901C
(en)
|
2007-07-20 |
2015-12-29 |
Nerviano Medical Sciences S.R.L. |
Substituted indazole derivatives active as kinase inhibitors
|
WO2009017838A2
(en)
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
WO2009023540A1
(en)
|
2007-08-10 |
2009-02-19 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
KR20100083170A
(ko)
|
2007-10-16 |
2010-07-21 |
와이어쓰 엘엘씨 |
티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 mTOR 키나제 및 PI3 키나제 억제제로서의 용도
|
CN101909647A
(zh)
|
2007-10-23 |
2010-12-08 |
诺瓦提斯公司 |
TrkB抗体用于治疗呼吸病症的用途
|
WO2009060197A1
(en)
|
2007-11-08 |
2009-05-14 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazopyridazines for use as protein kinase inhibitors
|
WO2009070567A1
(en)
|
2007-11-28 |
2009-06-04 |
Schering Corporation |
2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
|
JP5400791B2
(ja)
|
2007-12-04 |
2014-01-29 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
CN102015769B
(zh)
|
2008-01-17 |
2014-12-10 |
Irm责任有限公司 |
改进的抗-trkb抗体
|
US20090227556A1
(en)
|
2008-01-31 |
2009-09-10 |
Eisai R&D Management Co., Ltd. |
Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
|
DK2273975T3
(da)
|
2008-03-03 |
2014-06-30 |
Ucb Pharma Sa |
Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
|
KR100963051B1
(ko)
|
2008-03-14 |
2010-06-09 |
광동제약 주식회사 |
입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물
|
WO2009118411A2
(en)
|
2008-03-28 |
2009-10-01 |
Nerviano Medical Sciences S.R.L. |
3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
US20090275622A1
(en)
|
2008-04-30 |
2009-11-05 |
Prasoona Linga |
Nizatidine formulations
|
WO2009140128A2
(en)
|
2008-05-13 |
2009-11-19 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
PE20091846A1
(es)
|
2008-05-19 |
2009-12-16 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
AU2009248774B2
(en)
|
2008-05-23 |
2012-05-31 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
JP5767965B2
(ja)
|
2008-06-10 |
2015-08-26 |
プレキシコン インコーポレーテッドPlexxikon Inc. |
キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症
|
US8946226B2
(en)
|
2008-07-29 |
2015-02-03 |
Nerviano Medical Sciences S.R.L. |
Use of CDK inhibitor for the treatment of glioma
|
WO2010031816A1
(en)
|
2008-09-19 |
2010-03-25 |
Nerviano Medical Sciences S.R.L. |
3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
|
RS53350B
(en)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
|
KR101634833B1
(ko)
|
2008-10-22 |
2016-06-29 |
어레이 바이오파마 인크. |
TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물
|
EP2348860B1
(en)
|
2008-10-31 |
2015-05-27 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
JP2012509859A
(ja)
|
2008-11-24 |
2012-04-26 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
中皮腫の治療のためのcdk阻害物質
|
JO3265B1
(ar)
|
2008-12-09 |
2018-09-16 |
Novartis Ag |
مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
|
US9364477B2
(en)
|
2009-02-12 |
2016-06-14 |
Cell Signaling Technology, Inc. |
Mutant ROS expression in human cancer
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
US8546413B2
(en)
|
2009-06-15 |
2013-10-01 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
CN102821607B
(zh)
|
2009-12-21 |
2014-12-17 |
萨穆梅德有限公司 |
1H-吡唑并[3,4-b]吡啶及其治疗应用
|
JP5883395B2
(ja)
|
2010-01-29 |
2016-03-15 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
タンパク質キナーゼモジュレーターとしての6,7−ジヒドロイミダゾ[1,5−a]ピラジン−8(5h)−オン誘導体
|
EP2536414B1
(en)
|
2010-02-18 |
2016-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for preventing cancer metastasis
|
US9469876B2
(en)
|
2010-04-06 |
2016-10-18 |
Caris Life Sciences Switzerland Holdings Gmbh |
Circulating biomarkers for metastatic prostate cancer
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
EP2918588B1
(en)
|
2010-05-20 |
2017-05-03 |
Array Biopharma, Inc. |
Macrocyclic compounds as TRK kinase inhibitors
|
ES2873933T3
(es)
|
2010-06-09 |
2021-11-04 |
Dana Farber Cancer Inst Inc |
Una mutación de MEK1 que confiere resistencia a inhibidores de RAF y de MEK
|
RS63063B1
(sr)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S A |
Anti-ngf antitela i njihova upotreba
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
CN103619879A
(zh)
|
2010-12-01 |
2014-03-05 |
奥尔德生物控股有限责任公司 |
抗ngf组合物及其用途
|
BR112013018515B1
(pt)
|
2011-01-26 |
2021-06-29 |
Nerviano Medical Sciences S.R.I |
Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
|
WO2012101029A1
(en)
|
2011-01-26 |
2012-08-02 |
Nerviano Medical Sciences S.R.L. |
Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2678336B1
(en)
|
2011-02-24 |
2016-04-20 |
Nerviano Medical Sciences S.r.l. |
Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
|
CA2828219A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Pyrazolo [1,5-a] pyridines as trk inhibitors
|
JP5976778B2
(ja)
|
2011-04-11 |
2016-08-24 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
|
EP2699564B1
(en)
|
2011-04-19 |
2016-12-14 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinyl-pyrroles active as kinase inhibitors
|
BR112013028733B1
(pt)
|
2011-05-12 |
2022-05-10 |
Nerviano Medical Sciences S.R.L |
Derivados de indazol substituiídos ativos como inibidores de quinase
|
MY173181A
(en)
|
2011-05-13 |
2020-01-02 |
Array Biopharma Inc |
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
|
EP2736514B1
(en)
|
2011-07-28 |
2017-10-18 |
Nerviano Medical Sciences S.r.l. |
Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
|
JP5998223B2
(ja)
|
2011-10-07 |
2016-09-28 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤としての置換3,4−ジヒドロピロロ[1,2−a]ピラジン−1(2H)−オン誘導体
|
WO2013050448A1
(en)
|
2011-10-07 |
2013-04-11 |
Nerviano Medical Sciences S.R.L. |
4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
MX2014005632A
(es)
|
2011-11-14 |
2014-10-17 |
Tesaro Inc |
Modulacion de ciertas cinasas de tirosina.
|
BR112014014276A2
(pt)
|
2011-12-12 |
2017-06-13 |
Dr Reddys Laboratories Ltd |
composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
ES2605388T3
(es)
|
2012-04-26 |
2017-03-14 |
Ono Pharmaceutical Co., Ltd. |
Compuesto inhibidor de Trk
|
JP2013226108A
(ja)
|
2012-04-27 |
2013-11-07 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
KR102151963B1
(ko)
|
2012-05-23 |
2020-09-07 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
N-[5-(3,5-디플루오로-벤질)-1h-인다졸-3-일]-4-(4-메틸-피페라진-1-일)-2-(테트라하이드로-피란-4-일아미노)-벤즈아미드의 제조 방법
|
TWI585088B
(zh)
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
|
KR20150023059A
(ko)
|
2012-06-28 |
2015-03-04 |
맥네일-피피씨, 인코포레이티드 |
라세카도트릴 액체 조성물
|
SG11201500125QA
(en)
|
2012-07-11 |
2015-02-27 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
EP2689778A1
(en)
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Derivatives of azaindoles or diazaindoles for treating pain
|
WO2014019908A2
(en)
|
2012-08-02 |
2014-02-06 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrroles active as kinases inhibitors
|
US20150218652A1
(en)
|
2012-08-31 |
2015-08-06 |
The Regents Of The Unversity Of Colorado, A Body Corporate |
Methods for diagnosis and treatment of cancer
|
US20150238477A1
(en)
|
2012-09-07 |
2015-08-27 |
Exelixis, Inc. |
Method of Treating Lung Adenocarcinoma
|
US20140084039A1
(en)
|
2012-09-24 |
2014-03-27 |
Electro Scientific Industries, Inc. |
Method and apparatus for separating workpieces
|
JP2014082984A
(ja)
|
2012-10-23 |
2014-05-12 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
ES2949394T3
(es)
|
2012-11-05 |
2023-09-28 |
Found Medicine Inc |
Moléculas de fusión novedosas y usos de las mismas
|
WO2014071358A2
(en)
*
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
CN104870446B
(zh)
|
2012-11-07 |
2019-08-13 |
内尔维阿诺医学科学有限公司 |
取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
|
UA116455C2
(uk)
|
2012-11-13 |
2018-03-26 |
Еррей Біофарма Інк. |
Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
HUE031557T2
(en)
|
2012-11-13 |
2017-07-28 |
Array Biopharma Inc |
Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
WO2014078331A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
KR20150090116A
(ko)
|
2012-11-29 |
2015-08-05 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
종양 전이를 예방하고, 암을 치료하고 예후를 예측하며, 추정상의 전이 억제인자 물질을 확인하는 방법
|
US9447135B2
(en)
|
2012-12-14 |
2016-09-20 |
University Of Kentucky Research Foundation |
Semi-synthetic mithramycin derivatives with anti-cancer activity
|
US9127055B2
(en)
|
2013-02-08 |
2015-09-08 |
Astellas Pharma Inc. |
Method of treating pain with anti-human NGF antibody
|
MX353336B
(es)
|
2013-02-19 |
2018-01-09 |
Ono Pharmaceutical Co |
Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
|
WO2014130975A1
(en)
|
2013-02-22 |
2014-08-28 |
Bastian Boris C |
Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
|
WO2014134096A1
(en)
|
2013-02-27 |
2014-09-04 |
Oregon Health & Science University |
Methods of treating cancers characterized by aberrent ros1 activity
|
WO2014152965A2
(en)
*
|
2013-03-14 |
2014-09-25 |
The Children's Hospital Of Philadelphia |
Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
|
EP2968551B1
(en)
|
2013-03-15 |
2021-05-05 |
The Trustees of Columbia University in the City of New York |
Fusion proteins and methods thereof
|
WO2014152777A2
(en)
|
2013-03-15 |
2014-09-25 |
Insight Genetics, Inc. |
Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
|
US9499522B2
(en)
|
2013-03-15 |
2016-11-22 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
EP3795696B1
(en)
|
2013-03-15 |
2023-04-26 |
The Board of Trustees of the Leland Stanford Junior University |
Identification and use of circulating nucleic acid tumor markers
|
WO2014150751A2
(en)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Biomarkers associated with brm inhibition
|
US8937071B2
(en)
|
2013-03-15 |
2015-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds as rearranged during transfection (RET) inhibitors
|
WO2014172046A2
(en)
|
2013-04-17 |
2014-10-23 |
Life Technologies Corporation |
Gene fusions and gene variants associated with cancer
|
US10072298B2
(en)
|
2013-04-17 |
2018-09-11 |
Life Technologies Corporation |
Gene fusions and gene variants associated with cancer
|
WO2014184069A1
(en)
|
2013-05-14 |
2014-11-20 |
Nerviano Medical Sciences S.R.L. |
Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
|
BR112015028845A2
(pt)
|
2013-05-30 |
2017-07-25 |
Plexxikon Inc |
compostos para a modulação da quinase e indicações da mesma
|
RU2656591C2
(ru)
|
2013-07-11 |
2018-06-06 |
Бетта Фармасьютикалз Ко., Лтд |
Модуляторы протеин-тирозинкиназы и способы их применения
|
WO2015012397A1
(ja)
|
2013-07-26 |
2015-01-29 |
公益財団法人がん研究会 |
Ntrk3融合体の検出法
|
WO2015017528A1
(en)
|
2013-07-30 |
2015-02-05 |
Blueprint Medicines Corporation |
Pik3c2g fusions
|
EP3628749A1
(en)
|
2013-07-30 |
2020-04-01 |
Blueprint Medicines Corporation |
Ntrk2 fusions
|
WO2015039006A1
(en)
*
|
2013-09-16 |
2015-03-19 |
The General Hospital Corporation |
Methods of treating cancer
|
ES2923888T3
(es)
|
2013-10-17 |
2022-10-03 |
Blueprint Medicines Corp |
Procedimiento para preparar composiciones útiles para tratar trastornos relacionados con la KIT
|
US9334263B2
(en)
|
2013-10-17 |
2016-05-10 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
US9511050B2
(en)
|
2013-10-24 |
2016-12-06 |
Georgetown University |
Methods and compositions for treating cancer
|
WO2015061572A1
(en)
|
2013-10-25 |
2015-04-30 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
WO2015064621A1
(ja)
|
2013-10-29 |
2015-05-07 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
KR102267407B1
(ko)
*
|
2014-01-14 |
2021-06-23 |
주식회사 엘지화학 |
대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
ES2735729T3
(es)
|
2014-01-24 |
2019-12-20 |
Turning Point Therapeutics Inc |
Macrociclos de diarilo como moduladores de proteínas cinasas
|
ES2874533T3
(es)
|
2014-02-05 |
2021-11-05 |
VM Oncology LLC |
Composiciones de compuestos y usos de los mismos
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
WO2015161277A1
(en)
|
2014-04-18 |
2015-10-22 |
Blueprint Medicines Corporation |
Met fusions
|
EP3132056B1
(en)
|
2014-04-18 |
2021-11-24 |
Blueprint Medicines Corporation |
Pik3ca fusions
|
SI3154959T1
(sl)
|
2014-05-15 |
2019-10-30 |
Array Biopharma Inc |
1-((3S,4R)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4- metil-3-(2-metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)urea kot inhibitor TrkA kinaze
|
WO2015183836A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015183837A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015184443A1
(en)
|
2014-05-30 |
2015-12-03 |
The Regents Of The University Of Colorado |
Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
|
US10378063B2
(en)
|
2014-06-10 |
2019-08-13 |
Blueprint Medicines Corporation |
RAF1 fusions
|
WO2015191667A1
(en)
|
2014-06-10 |
2015-12-17 |
Blueprint Medicines Corporation |
Pkn1 fusions
|
EP3169808B1
(en)
|
2014-07-17 |
2019-05-22 |
Blueprint Medicines Corporation |
Trio:tert fusion in cancer
|
US10370725B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
FGR fusions
|
US10370724B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
PRKC fusions
|
EP3185870A4
(en)
|
2014-08-01 |
2018-06-20 |
Pharmacyclics LLC |
Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
|
WO2016022569A1
(en)
|
2014-08-04 |
2016-02-11 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
CN106573913B
(zh)
|
2014-08-18 |
2019-11-19 |
小野药品工业株式会社 |
抑制Trk的化合物的酸加成盐
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
MX2017006366A
(es)
|
2014-11-14 |
2018-02-01 |
Nerviano Medical Sciences Srl |
Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
|
DK3699181T3
(da)
|
2014-11-16 |
2023-03-20 |
Array Biopharma Inc |
Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
|
WO2016081450A1
(en)
|
2014-11-18 |
2016-05-26 |
Blueprint Medicines Corporation |
Prkacb fusions
|
CA2971024C
(en)
|
2014-12-15 |
2023-09-26 |
Handok Inc. |
Fused ring heteroaryl compounds and their use as trk inhibitors
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
EP3303382A4
(en)
|
2015-05-29 |
2018-12-19 |
Ignyta, Inc. |
Compositions and methods for treating patients with rtk mutant cells
|
CA2988423A1
(en)
|
2015-06-01 |
2016-12-08 |
Loxo Oncology, Inc. |
Methods of diagnosing and treating cancer
|
AU2015101722A4
(en)
|
2015-06-19 |
2016-05-19 |
Macau University Of Science And Technology |
Oncogenic ros1 and alk kinase inhibitor
|
US9782400B2
(en)
|
2015-06-19 |
2017-10-10 |
Macau University Of Science And Technology |
Oncogenic ROS1 and ALK kinase inhibitor
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
US10316044B2
(en)
|
2015-07-02 |
2019-06-11 |
Tp Therapeutics, Inc. |
Chiral diaryl macrocycles as modulators of protein kinases
|
BR112018008357A2
(pt)
|
2015-10-26 |
2018-11-27 |
Array Biopharma Inc |
mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
|
WO2017127835A2
(en)
*
|
2016-01-22 |
2017-07-27 |
The Medicines Company |
Aqueous formulations and methods of preparation and use thereof
|
TW201733580A
(zh)
|
2016-03-11 |
2017-10-01 |
小野藥品工業股份有限公司 |
Trk抑制劑抵抗性的癌治療劑
|
TN2019000332A1
(en)
|
2016-04-04 |
2021-05-07 |
Loxo Oncology Inc |
Methods of treating pediatric cancers
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
RU2751767C2
(ru)
|
2016-04-04 |
2021-07-16 |
Локсо Онколоджи, Инк. |
Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
|
US20210030737A1
(en)
|
2016-04-19 |
2021-02-04 |
Exelixis, Inc. |
Triple Negative Breast Cancer Treatment Method
|
LT3458456T
(lt)
|
2016-05-18 |
2021-02-25 |
Loxo Oncology, Inc. |
(s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas
|
WO2017201156A1
(en)
|
2016-05-18 |
2017-11-23 |
Duke University |
Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
WO2019084285A1
(en)
|
2017-10-26 |
2019-05-02 |
Qian Zhao |
FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
|
EP3773725A1
(en)
|
2018-03-29 |
2021-02-17 |
Loxo Oncology Inc. |
Treatment of trk-associated cancers
|